| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 221,184 | |||
| Selling, general and administrative | 98,735 | |||
| Total operating expenses | 319,919 | |||
| Loss from operations | -319,919 | |||
| Research and development incentives | 1,604 | |||
| Investment income | 13,625 | |||
| Interest expense on finance lease liability | 2,063 | |||
| Interest expense on debt obligations | 6,796 | |||
| Other expense | -942 | |||
| Total other income, net | 5,428 | |||
| Loss before income taxes | -314,491 | |||
| Income tax (benefit) provision | -551 | |||
| Net loss | -313,940 | |||
| Basic EPS | -3.38 | |||
| Diluted EPS | -3.38 | |||
| Basic Average Shares | 92,803,711 | |||
| Diluted Average Shares | 92,803,711 | |||
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)